CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 1,110,000 shares, an increase of 63.5% from the September 30th total of 679,000 shares. Based on an average trading volume of 13,620,000 shares, the days-to-cover ratio is currently 0.1 days.

CNS Pharmaceuticals Price Performance

CNS Pharmaceuticals stock opened at $0.15 on Tuesday. The company’s 50-day moving average is $0.14 and its 200-day moving average is $3.49. The firm has a market capitalization of $4.85 million, a PE ratio of 0.00 and a beta of 2.57. CNS Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $137.50.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Tuesday, September 10th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC increased its holdings in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,246 shares of the company’s stock after buying an additional 81,094 shares during the period. Virtu Financial LLC owned 0.80% of CNS Pharmaceuticals worth $34,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.